LivaNova PLC Company Profile (NASDAQ:LIVN)

About LivaNova PLC (NASDAQ:LIVN)

LivaNova PLC logoLivaNova PLC is a medical device company focused on the development and delivery of therapeutic solutions. The Company's segments include Cardiac Surgery, Cardiac Rhythm Management, Neuromodulation and Other. The Cardiac Surgery segment is engaged in the development, production and sale of cardiovascular surgery products. Cardiac Surgery products include oxygenators, heart-lung machines, autotransfusion, mechanical heart valves and tissue heart valves. The Cardiac Rhythm Management segment is engaged in the development, manufacturing and marketing of products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. Cardiac Rhythm Management products include high-voltage defibrillators Cardiac Resynchronization Therapy device (CRT-D) and low-voltage pacemakers. The Neuromodulation segment is engaged in the design, development and marketing of neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment resistant depression.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: N/A
  • Symbol: NASDAQ:LIVN
  • CUSIP: N/A
  • Web:
  • Market Cap: $3.36503 billion
  • Outstanding Shares: 48,838,000
Average Prices:
  • 50 Day Moving Avg: $62.98
  • 200 Day Moving Avg: $57.94
  • 52 Week Range: $40.83 - $70.14
  • Trailing P/E Ratio: 124.71
  • Foreward P/E Ratio: 19.24
  • P/E Growth: 1.54
Sales & Book Value:
  • Annual Revenue: $1.21 billion
  • Price / Sales: 2.82
  • Book Value: $38.28 per share
  • Price / Book: 1.82
  • EBIDTA: $191.69 million
  • Net Margins: 2.26%
  • Return on Equity: 9.08%
  • Return on Assets: 6.61%
  • Debt-to-Equity Ratio: 0.04%
  • Current Ratio: 1.96%
  • Quick Ratio: 1.36%
  • Average Volume: 532,862 shs.
  • Beta: 0.58
  • Short Ratio: 6.85

Frequently Asked Questions for LivaNova PLC (NASDAQ:LIVN)

What is LivaNova PLC's stock symbol?

LivaNova PLC trades on the NASDAQ under the ticker symbol "LIVN."

How were LivaNova PLC's earnings last quarter?

LivaNova PLC (NASDAQ:LIVN) released its quarterly earnings results on Wednesday, August, 9th. The company reported $1.01 EPS for the quarter, beating analysts' consensus estimates of $0.82 by $0.19. The business earned $321.40 million during the quarter, compared to analyst estimates of $315.75 million. LivaNova PLC had a return on equity of 9.08% and a net margin of 2.26%. LivaNova PLC's revenue was up .1% compared to the same quarter last year. View LivaNova PLC's Earnings History.

When will LivaNova PLC make its next earnings announcement?

LivaNova PLC is scheduled to release their next quarterly earnings announcement on Wednesday, November, 1st 2017. View Earnings Estimates for LivaNova PLC.

What guidance has LivaNova PLC issued on next quarter's earnings?

LivaNova PLC issued an update on its FY17 earnings guidance on Wednesday, August, 9th. The company provided earnings per share guidance of $3.10-3.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.10.

Where is LivaNova PLC's stock going? Where will LivaNova PLC's stock price be in 2017?

7 brokerages have issued 12 month price objectives for LivaNova PLC's stock. Their predictions range from $50.00 to $83.00. On average, they expect LivaNova PLC's share price to reach $71.50 in the next twelve months. View Analyst Ratings for LivaNova PLC.

What are analysts saying about LivaNova PLC stock?

Here are some recent quotes from research analysts about LivaNova PLC stock:

  • 1. Canaccord Genuity analysts commented, "We come out of LIVN’s Investor Day with a better understanding of management’s approach to turning around this business and strategic plan for augmenting long-term, organic growth; however, we do not see a high-probability pathway to material organic growth acceleration near term. Moreover, while we remain very intrigued by the firm’s big shots on goal (i.e." (9/20/2017)
  • 2. Needham & Company LLC analysts commented, "LIVN announced that it is exploring strategic options for its low growth and low margin CRM business. This shouldn’t come as a huge surprise since management had previously hinted a potential sale of the CRM business. We think a CRM sale would increase LIVN’s revenue growth; the EPS impact hinges on price, CRM margins, and use of proceeds. We think a sale would be neutral to slightly dilutive if the proceeds were used for share repurchases and/or debt repayment though we note that there would likely be near-term hit to EPS between when the sale is announced and when LIVN is able to deploy the proceeds to offset any dilution." (9/14/2017)
  • 3. BTIG Research analysts commented, "Last week, while we were at our Snowbird conference, LIVN reported Q4 results and released initial FY17 guidance. Once again, we are lowering our estimates for LIVN. While shares are inexpensive, we do not see how it will grow in the future unless major M&A or R&D efforts take place, moving LIVN into new markets. Given most of LIVN’s markets are flat to declining, we would be inclined to wait for the company to show intentions to enter new markets before recommending shares. We don’t expect an inflection point on cardiac surgery anytime soon and while new iterations in Neuromod may pad growth in 2H17, we think the lower end of the 1-3% revenue growth guidance would be a good achievement. There remain considerable areas of opportunity on the synergy side, which should support EPS growth. With the first innings of physical integration behind them, we think the co. is in a better position to focus on more sizeable areas of savings such as purchasing/direct procurement. However, we think the lack of revenue growth is more important than synergies and we reiterate our Neutral rating." (3/10/2017)

Who are some of LivaNova PLC's key competitors?

Who owns LivaNova PLC stock?

LivaNova PLC's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (10.42%), FMR LLC (9.84%), BlackRock Inc. (9.52%), State Street Corp (3.81%), Capital Research Global Investors (3.42%) and Koch Industries Inc. (2.92%). Company insiders that own LivaNova PLC stock include Alfred J Novak, Daniel Jeffrey Moore, Hugh M Morrison, Jacques Gutedel, Sharon O'kane and Two SCA Equinox. View Institutional Ownership Trends for LivaNova PLC.

Who sold LivaNova PLC stock? Who is selling LivaNova PLC stock?

LivaNova PLC's stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd, Renaissance Technologies LLC, Employees Retirement System of Texas, OxFORD Asset Management LLP, FMR LLC, Janney Montgomery Scott LLC, JPMorgan Chase & Co. and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold LivaNova PLC stock in the last year include Alfred J Novak, Daniel Jeffrey Moore and Hugh M Morrison. View Insider Buying and Selling for LivaNova PLC.

Who bought LivaNova PLC stock? Who is buying LivaNova PLC stock?

LivaNova PLC's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Koch Industries Inc., State Street Corp, HealthCor Management L.P., Franklin Resources Inc., Dimensional Fund Advisors LP, Redmile Group LLC and Janus Henderson Group PLC. View Insider Buying and Selling for LivaNova PLC.

How do I buy LivaNova PLC stock?

Shares of LivaNova PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is LivaNova PLC's stock price today?

One share of LivaNova PLC stock can currently be purchased for approximately $69.84.

MarketBeat Community Rating for LivaNova PLC (NASDAQ LIVN)
Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  73 (Vote Outperform)
Underperform Votes:  81 (Vote Underperform)
Total Votes:  154
MarketBeat's community ratings are surveys of what our community members think about LivaNova PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for LivaNova PLC (NASDAQ:LIVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $71.50 (2.38% upside)

Analysts' Ratings History for LivaNova PLC (NASDAQ:LIVN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/20/2017Canaccord GenuityReiterated RatingHold$71.00LowView Rating Details
9/15/2017Jefferies Group LLCBoost Price TargetBuy$76.00 -> $80.00LowView Rating Details
9/15/2017Needham & Company LLCUpgradeHold -> Buy$83.00LowView Rating Details
9/12/2017Piper Jaffray CompaniesReiterated RatingOverweight -> Overweight$75.00LowView Rating Details
8/15/2017WBB SecuritiesDowngradeHold -> Sell$50.00LowView Rating Details
8/11/2017Berenberg BankReiterated RatingBuy$70.00LowView Rating Details
3/10/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
2/29/2016Kepler Capital MarketsBoost Price TargetHold$63.00 -> $66.00N/AView Rating Details
(Data available from 9/24/2015 forward)


Earnings History for LivaNova PLC (NASDAQ:LIVN)
Earnings by Quarter for LivaNova PLC (NASDAQ:LIVN)
Earnings History by Quarter for LivaNova PLC (NASDAQ LIVN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/9/2017Q2 2017$0.82$1.01$315.75 million$321.40 millionViewListenView Earnings Details
5/3/20173/31/2017$0.68$0.71$285.10 millionViewListenView Earnings Details
3/1/2017Q416$0.79$0.82$301.45 million$310.60 millionViewListenView Earnings Details
11/2/2016Q316$0.76$0.78$299.40 million$295.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for LivaNova PLC (NASDAQ:LIVN)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)


Dividend History for LivaNova PLC (NASDAQ:LIVN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for LivaNova PLC (NASDAQ:LIVN)
Insider Ownership Percentage: 0.28%
Institutional Ownership Percentage: 82.26%
Insider Trades by Quarter for LivaNova PLC (NASDAQ:LIVN)
Institutional Ownership by Quarter for LivaNova PLC (NASDAQ:LIVN)
Insider Trades by Quarter for LivaNova PLC (NASDAQ:LIVN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/15/2017Daniel Jeffrey MooreDirectorSell1,000$68.55$68,550.00View SEC Filing  
8/15/2017Daniel Jeffrey MooreDirectorSell1,000$60.76$60,760.00View SEC Filing  
7/17/2017Daniel Jeffrey MooreDirectorSell1,000$61.55$61,550.00View SEC Filing  
6/15/2017Daniel Jeffrey MooreDirectorSell1,000$60.80$60,800.00View SEC Filing  
5/23/2017Sharon O'kaneDirectorBuy1,000$58.58$58,580.00View SEC Filing  
5/22/2017Alfred J NovakDirectorSell1,000$58.49$58,490.00View SEC Filing  
5/5/2017Hugh M MorrisonDirectorSell3,215$55.89$179,686.35View SEC Filing  
4/17/2017Daniel Jeffrey MooreDirectorSell1,000$51.32$51,320.00View SEC Filing  
3/15/2017Daniel Jeffrey MooreDirectorSell1,000$50.21$50,210.00View SEC Filing  
9/22/2016Two S.C.A. EquinoxMajor ShareholderSell185,000$61.54$11,384,900.00View SEC Filing  
9/21/2016Two S.C.A. EquinoxMajor ShareholderSell391,379$60.69$23,752,791.51View SEC Filing  
9/16/2016Two S.C.A. EquinoxMajor ShareholderSell75,213$59.86$4,502,250.18View SEC Filing  
9/13/2016Two S.C.A. EquinoxMajor ShareholderSell25,408$60.02$1,524,988.16View SEC Filing  
9/8/2016Two S.C.A. EquinoxMajor ShareholderSell208,000$60.52$12,588,160.00View SEC Filing  
8/9/2016Jacques GutedelInsiderSell4,000$60.52$242,080.00View SEC Filing  
5/24/2016Daniel Jeffrey MooreDirectorSell1,000$50.07$50,070.00View SEC Filing  
5/19/2016Hugh M MorrisonDirectorSell3,600$48.00$172,800.00View SEC Filing  
5/6/2016Alfred J NovakDirectorSell4,000$51.12$204,480.00View SEC Filing  
4/15/2016Daniel Jeffrey MooreDirectorSell1,000$54.81$54,810.00View SEC Filing  
3/15/2016Daniel Jeffrey MooreDirectorSell1,000$56.88$56,880.00View SEC Filing  
2/16/2016Daniel Jeffrey MooreDirectorSell1,000$56.88$56,880.00View SEC Filing  
1/15/2016Daniel Jeffrey MooreDirectorSell1,000$52.64$52,640.00View SEC Filing  
12/15/2015Daniel Jeffrey MooreDirectorSell2,500$53.97$134,925.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for LivaNova PLC (NASDAQ:LIVN)
Latest Headlines for LivaNova PLC (NASDAQ:LIVN)
DateHeadline logoLivaNova PLC (LIVN) Stock Rating Reaffirmed by Canaccord Genuity - September 20 at 9:42 AM logoLivaNova PLC (LIVN) Director Daniel Jeffrey Moore Sells 1,000 Shares - September 19 at 4:28 PM logoLivaNova PLC (LIVN) Receives Consensus Rating of "Hold" from Analysts - September 17 at 9:02 AM logoLivaNova PLC (LIVN) Lifted to Buy at Needham & Company LLC - September 16 at 8:26 PM logoLivaNova PLC (LIVN) PT Raised to $80.00 - September 15 at 2:34 PM logoLivaNova PLC (LIVN) Upgraded at Needham & Company LLC - September 15 at 8:30 AM logoLivaNova Defines Strategic Outlook at Investor Day - September 15 at 5:56 AM logoLivaNova to Explore Strategic Options for Cardiac Rhythm Management Business Franchise - September 14 at 7:11 AM logoLivaNova PLC (LIVN) Now Covered by Analysts at Piper Jaffray Companies - September 12 at 12:34 PM logoLivaNova Announces Publication of Literature Review Highlighting the Clinical Value and Safety of the Perceval Sutureless Valve for Aortic Valve Replacement - September 11 at 10:33 PM logoJefferies Group Comments on LivaNova PLC's Q3 2017 Earnings (LIVN) - September 11 at 1:42 AM logoLivaNova PLC (LIVN) Coverage Initiated by Analysts at Jefferies Group LLC - September 8 at 8:42 PM logoLivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 29, 2017 - August 30 at 6:07 AM logoAnalyzing LivaNova PLC (LIVN) and Align Technology (ALGN) - August 24 at 10:26 PM logoLivaNova PLC (LIVN) Receives Average Recommendation of "Hold" from Analysts - August 23 at 9:16 AM logoFinancial Review: LivaNova PLC (LIVN) & InspireMD (NSPR) - August 20 at 2:28 PM logoLivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 18, 2017 - August 18 at 8:44 PM logoInsider Selling: LivaNova PLC (LIVN) Director Sells 1,000 Shares of Stock - August 17 at 10:24 AM logoLivaNova Plc – Value Analysis (NASDAQ:LIVN) : August 17, 2017 - August 17 at 1:52 AM logoLivaNova PLC (LIVN) Downgraded to "Sell" at WBB Securities - August 15 at 11:20 AM logoLivaNova PLC (LIVN) Receives "Buy" Rating from Berenberg Bank - August 12 at 5:42 PM logoSee what the IHS Markit Score report has to say about LivaNova PLC. - August 12 at 2:39 AM logoLivaNova PLC (NASDAQ:LIVN) Posts Earnings Results, Beats Expectations By $0.19 EPS - August 11 at 11:46 PM logoLivaNova plc (LIVN) Tops Q2 EPS by 19c, Beats on Revenues; Reaffirms FY17 EPS Mid-Point Guidance Above Consensus - August 10 at 2:26 AM logoLivaNova PLC beats by $0.19, beats on revenue - August 10 at 2:26 AM logoCORRECTING and REPLACING LivaNova Reports Second Quarter 2017 Results - August 10 at 2:26 AM logoLivaNova PLC (LIVN) Updates FY17 Earnings Guidance - August 9 at 8:46 AM logoLivaNova’s Perceval Sutureless Aortic Heart Valve Awarded New Technology Add-on Payment from the Center for Medicare and Medicaid Services - August 5 at 1:30 AM logoLivaNova Plc breached its 50 day moving average in a Bearish Manner : LIVN-US : August 3, 2017 - August 4 at 12:14 AM logoLivaNova PLC (NASDAQ:LIVN) Set to Announce Quarterly Earnings on Wednesday - August 2 at 7:26 AM logoVNS Therapy Receives CE Mark for Expanded MRI Labeling - August 1 at 5:54 AM logoLivaNova PLC (LIVN) vs. CareFusion (CFN) Head to Head Contrast - July 24 at 10:18 PM logoInsider Selling: LivaNova PLC (NASDAQ:LIVN) Director Sells 1,000 Shares of Stock - July 18 at 1:44 PM logoLivaNova PLC (NASDAQ:LIVN) Short Interest Update - July 16 at 7:23 AM logoETFs with exposure to LivaNova Plc : July 4, 2017 - July 4 at 6:16 PM logoFDA Approves VNS Therapy Treatment for Drug-Resistant Epilepsy in Children as Young as Four Years Old - June 30 at 1:05 AM logoLivaNova to Host Conference Call for Second Quarter 2017 Results - June 27 at 6:28 PM logoLivaNova plc (LIVN) Receives FDA Approval for Expanded MRI Labeling - June 21 at 4:06 PM logoVNS Therapy Receives FDA Approval for Expanded MRI Labeling - June 21 at 4:06 PM logoComparing Zimmer Biomet Holdings (ZBH) & LivaNova PLC (LIVN) - June 18 at 6:04 PM logoETFs with exposure to LivaNova Plc : June 16, 2017 - June 16 at 7:15 PM logoLivaNova Plc :LIVN-US: Earnings Analysis: Q1, 2017 By the Numbers : June 14, 2017 - June 14 at 10:31 AM logoLivaNova Appoints Keyna Skeffington as Senior Vice President and General Counsel - June 12 at 9:40 AM logoLivaNova PLC (LIVN) and West Pharmaceutical Services (WST) Financial Comparison - June 9 at 10:32 PM logoLivaNova PLC (LIVN) Director Sharon O'kane Purchases 1,000 Shares - May 24 at 8:24 PM logoAlfred J. Novak Sells 1,000 Shares of LivaNova PLC (LIVN) Stock - May 23 at 8:18 PM logoLivaNova (LIVN) Presents At Bank of America Merrill Lynch 2017 Health Care Conference - Slideshow - May 19 at 6:00 PM logoLivaNova PLC (LIVN) Director Hugh M. Morrison Sells 3,215 Shares - May 9 at 4:37 PM logoLivaNova PLC to Present at the Bank of America Merrill Lynch and Jefferies Conferences - May 9 at 12:00 PM logoLivaNova PLC (LIVN) Releases Earnings Results, Beats Estimates By $0.03 EPS - May 5 at 11:53 PM



LivaNova PLC (LIVN) Chart for Sunday, September, 24, 2017

This page was last updated on 9/24/2017 by Staff